Abstract
α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Current Bioactive Compounds
Title:Antiedematogenic Effect of α-Phellandrene in Animal Models
Volume: 12 Issue: 2
Author(s): Hálmisson D.S. Siqueira, Benedito P.S. Neto, Damião P. Sousa, Bruno S. Gomes, Francisco V.M. Cunha and Francisco A. Oliveira
Affiliation:
Keywords: Monoterpene, α-Phellandrene, anti-inflammatory activity, edema.
Abstract: α-phellandrene antiedematogenic effect (α-Phel) was evaluated in carrageenan, histamine, prostaglandin and substance P induced paw edema and croton oil, TPA and arachidonic acid induced ear edemain mice. Experimental protocols were approved by Ethical Committee for Animal Experimentation (CEEA/UFPI, Protocol Nº 010/2011). α-Phel (100 and 200 mg.kg-1, p.o.) reduced carrageenan and prostaglandina (40.97 % and 61.41 %, respectively) induced paw edema, in doses 50, 100 e 200 mg.kg-1, p.o. reduced histamina induced paw edema formation (31.27 %; 45.14 % e 47.29 %, respectively); on substance P induced paw edema the inhibition occurred when the animal were treated with 200 mg.kg-1 of α-Phel, p.o. (44.05 %).When administered topically, α-Phel (0.2 e 0.4 mg/ear) reduced croton oil (57.34 % e 62.42 %, respectively), TPA (48.29 % e 62.10 %, respectively)and arachidonic acid(0.4 mg/ear) induced ear edema (29.55 %).α-Phelpresents antiedematogenic activity in acute inflammation models.
Export Options
About this article
Cite this article as:
D.S. Siqueira Hálmisson, P.S. Neto Benedito, P. Sousa Damião, S. Gomes Bruno, V.M. Cunha Francisco and A. Oliveira Francisco, Antiedematogenic Effect of α-Phellandrene in Animal Models, Current Bioactive Compounds 2016; 12 (2) . https://dx.doi.org/10.2174/1573407212666160210231052
DOI https://dx.doi.org/10.2174/1573407212666160210231052 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in Drug Delivery of Polymeric Nano-Micelles
Current Drug Metabolism Update on Nitazoxanide: A Multifunctional Chemotherapeutic Agent
Current Drug Discovery Technologies Apoptosis: Its Functions and Control in the Ocular Lens
Current Molecular Medicine Dietary and Plant Polyphenols Exert Neuroprotective Effects and Improve Cognitive Function in Cerebral Ischemia
Recent Patents on Food, Nutrition & Agriculture Keratinocyte Growth Factor (KGF) in Hematology and Oncology
Current Pharmaceutical Design A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry Chaperoning the Cancer: The Proteostatic Functions of the Heat Shock Proteins in Cancer
Recent Patents on Anti-Cancer Drug Discovery Toll-Like Receptors and their Role in Renal Pathologies
Inflammation & Allergy - Drug Targets (Discontinued) HIV DNA and Immune Alteration During Successful HAART
Current HIV Research [General Articles] Intracellular Thiol Concentration Modulating Inflammatory Response: Influence on the Regulation of Cell Functions Through Cysteine Prodrug Approach
Current Medicinal Chemistry Recent Findings Regarding Pathogenesis and Prevention of Ventilator- Associated Pneumonia
Current Respiratory Medicine Reviews Purification of Transcription Factors and Identification with Mass Spectrometry
Current Analytical Chemistry Withdrawal Notice: COVID-19: Outbreak to Global
Anti-Infective Agents Alginate Based Nanocarriers for Drug Delivery Applications
Current Pharmaceutical Design New Agents Promote Neuroprotection in Parkinson’s Disease Models
CNS & Neurological Disorders - Drug Targets Dysfunctional Adaptive Immunity During Parasitic Infections
Current Immunology Reviews (Discontinued) The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
Current Pharmaceutical Design Risk Factors for Postembolization Syndrome After Transcatheter Arterial Chemoembolization
Current Medical Imaging May Adjuvant Therapy Play A Role for the Management of Renal Cell Carcinoma? A Review of Literature and Ongoing Trials
Anti-Cancer Agents in Medicinal Chemistry Targeting Vascular Niche by Parathyroid Hormone
Current Medicinal Chemistry